Market Price

63.44 

0.00 0.0%

as of Nov 08 '19

52 Week Range:

50.77 86.70


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California. As of November 8, 2019, Genomic Health, Inc. operates as a subsidiary of Exact Sciences Corporation.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 2.33
2.39
2.97
3.59
4.22
4.70
4.50
4.04
4.27
4.98
6.76
growth rate 2.6% 24.3% 20.9% 17.6% 11.4% -4.3% -10.2% 5.7% 16.6% 35.7%
Earnings BIT -16.15
-8.85
4.15
8.28
8.67
-12.41
-23.63
-27.89
-12.83
-3.17
30.00
growth rate 0.0% 100.0% 99.5% 4.7% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Avg.PE -35.70
-61.10
147.06
100.00
106.38
-17.65
-17.65
-17.65
-17.65
-224.13
159.43
growth rate 0.0% 100.0% -32.0% 6.4% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
ROA -18.43
-10.77
4.31
6.18
5.56
-7.71
-13.55
-17.98
-7.22
-1.78
9.07
growth rate 0.0% 100.0% 43.4% -10.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
ROE -23.43
-13.97
5.55
7.79
6.83
-9.40
-16.93
-23.37
-9.42
-2.24
11.20
growth rate 0.0% 100.0% 40.4% -12.3% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
ROIC -22.33
-14.52
5.26
7.65
6.67
-9.56
-17.06
-23.46
-9.67
-2.57
10.44
growth rate 0.0% 100.0% 45.4% -12.8% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Cur. Ratio 4.00
3.96
4.53
4.93
5.14
4.86
3.87
3.35
3.54
4.41
4.60
growth rate -1.0% 14.4% 8.8% 4.3% -5.5% -20.4% -13.4% 5.7% 24.6% 4.3%
Quick Ratio 3.73
3.67
4.22
4.65
4.79
4.52
3.61
3.10
3.21
4.07
4.37
growth rate -1.6% 15.0% 10.2% 3.0% -5.6% -20.1% -14.1% 3.6% 26.8% 7.4%
Leverage 1.31
1.29
1.29
1.24
1.22
1.22
1.28
1.32
1.29
1.23
1.24
growth rate -1.5% 0.0% -3.9% -1.6% 0.0% 4.9% 3.1% -2.3% -4.7% 0.8%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 8.80
11.10
14.30
21.08
22.25
29.45
34.92
37.16
35.18
31.16
51.53
growth rate 26.1% 28.8% 47.4% 5.6% 32.3% 18.6% 6.4% -5.3% -11.4% 65.4%
Acct.Payable 24.05
24.72
28.95
6.99
8.59
2.86
0.16
8.85
growth rate 2.8% 17.1% -75.9% 22.9% -66.6% -94.6% 5,572.4%
Cur.Assets 70.30
74.20
97.70
129.00
130.21
144.99
148.52
142.95
145.96
174.26
274.84
growth rate 5.6% 31.7% 32.0% 0.9% 11.4% 2.4% -3.8% 2.1% 19.4% 57.7%
Total Assets 86.70
88.10
110.90
143.00
153.73
177.03
185.92
184.62
201.11
231.62
334.37
growth rate 1.6% 25.9% 28.9% 7.5% 15.2% 5.0% -0.7% 8.9% 15.2% 44.4%
Cash 11.20
9.10
31.20
32.87
18.01
33.28
29.73
32.53
40.40
45.52
61.65
growth rate -18.8% 242.9% 5.4% -45.2% 84.8% -10.7% 9.4% 24.2% 12.7% 35.4%
Inventory 0.00 0.00 0.00 0.00 0.00
growth rate
Cur.Liabilities 17.60
18.70
21.60
26.14
25.34
29.83
38.34
42.67
41.18
39.52
59.78
growth rate 6.3% 15.5% 21.0% -3.1% 17.7% 28.5% 11.3% -3.5% -4.0% 51.3%
Liabilities 20.50
19.60
24.80
27.64
27.41
32.05
40.41
45.08
45.01
43.33
64.21
growth rate -4.4% 26.5% 11.5% -0.8% 17.0% 26.1% 11.6% -0.2% -3.7% 48.2%
LT Debt 0.20
0.00
0.00
0.00
0.00
growth rate -100.0%
Equity 66.20
68.50
86.10
115.36
126.33
144.98
145.51
139.54
156.11
188.29
270.16
growth rate 3.5% 25.7% 34.0% 9.5% 14.8% 0.4% -4.1% 11.9% 20.6% 43.5%
Common Shares 28.00
29.00
30.00
31.00
32.00
31.00
31.00
0.00
0.00
0.00
0.00
growth rate 3.6% 3.5% 3.3% 3.2% -3.1% 0.0% -100.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 10.10
3.70
4.40
6.18
10.06
11.01
10.46
23.48
19.79
13.28
10.08
growth rate -63.4% 18.9% 40.5% 62.6% 9.5% -5.0% 124.6% -15.7% -32.9% -24.1%
Cash Dividends 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA -0.82
4.80
21.60
22.60
25.96
8.55
2.29
-11.83
13.45
30.60
76.56
growth rate 100.0% 350.0% 4.6% 14.9% -67.1% -73.3% -100.0% 100.0% 127.5% 150.2%
FCF per Share -0.38
0.04
0.58
0.39
0.50
0.25
-0.34
-0.96
-0.23
0.08
1.41
growth rate 100.0% 1,350.0% -32.8% 28.2% -50.0% -100.0% 0.0% 0.0% 100.0% 1,662.5%
Sale Purchase of Stock 9.56
-11.33
16.57
12.03
12.20
17.01
21.78
growth rate -100.0% 100.0% -27.4% 1.4% 39.5% 28.0%
FCF -11.00
1.00
17.00
16.00
16.00
-2.00
-8.00
-35.00
-6.00
17.00
66.00
growth rate 100.0% 1,600.0% -5.9% 0.0% -100.0% 0.0% 0.0% 0.0% 100.0% 288.2%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 110.60
149.50
178.10
206.11
235.17
261.60
275.71
287.46
327.87
340.75
394.11
growth rate 35.2% 19.1% 15.7% 14.1% 11.2% 5.4% 4.3% 14.1% 3.9% 15.7%
Op.Income -17.50
-9.40
3.90
7.85
8.25
-12.76
-23.63
-27.89
-12.83
-3.17
30.00
growth rate 0.0% 100.0% 101.2% 5.1% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
IBT -16.20
-8.90
4.20
8.28
8.67
-12.41
-24.20
-34.30
-12.54
-2.35
26.92
growth rate 0.0% 100.0% 97.0% 4.8% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Net Income -16.10
-9.40
4.30
7.85
8.25
-12.76
-24.59
-33.31
-13.92
-3.86
25.68
growth rate 0.0% 100.0% 82.5% 5.1% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
EPS -0.57
-0.33
0.14
0.26
0.26
-0.42
-0.78
-1.03
-0.42
-0.11
0.68
growth rate 0.0% 100.0% 85.7% 0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 100.0%
Gross Profit 83.40
117.00
143.50
172.28
198.16
219.50
223.49
224.24
208.88
226.42
269.19
growth rate 40.3% 22.7% 20.1% 15.0% 10.8% 1.8% 0.3% -6.9% 8.4% 18.9%
R&D 28.60
35.70
33.20
39.86
49.10
64.18
49.60
44.86
56.82
52.83
growth rate 24.8% -7.0% 20.1% 23.2% 30.7% -22.7% -9.6% 26.7% -7.0%

Quarterly Statements

Item Name Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Earnings BIT 11.76
6.92
11.54
15.50
19.05
growth rate -41.2% 66.8% 34.3% 22.9%
Balance Sheet Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Acct.Receivable 51.55
51.53
59.25
54.31
55.88
growth rate 0.0% 15.0% -8.3% 2.9%
Acct.Payable 6.55
8.85
9.29
6.68
6.43
growth rate 35.2% 5.0% -28.1% -3.8%
Cur.Assets 246.70
274.84
280.65
312.23
345.04
growth rate 11.4% 2.1% 11.3% 10.5%
Total Assets 300.37
334.37
392.79
426.16
460.41
growth rate 11.3% 17.5% 8.5% 8.0%
Cash 69.24
61.65
101.41
90.93
71.96
growth rate -11.0% 64.5% -10.3% -20.9%
Inventory
growth rate
Cur.Liabilities 50.41
59.78
49.49
54.36
57.90
growth rate 18.6% -17.2% 9.9% 6.5%
Liabilities 54.35
64.21
104.91
108.94
111.04
growth rate 18.2% 63.4% 3.8% 1.9%
LT Debt 53.48
growth rate
Equity 246.02
270.16
287.88
317.22
349.37
growth rate 9.8% 6.6% 10.2% 10.1%
Common Shares 0.00 0.00 0.00 0.00 0.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Capital Expenditures 2.73
3.12
2.98
7.28
5.74
growth rate 14.5% -4.6% 144.5% -21.2%
Cash Dividends
growth rate
Cash From OA 29.75
24.58
-3.67
38.38
32.17
growth rate -17.4% -100.0% 100.0% -16.2%
Sale Purchase of Stock
growth rate
FCF 27.02
21.45
-6.65
31.10
26.43
growth rate -20.6% -100.0% 100.0% -15.0%
Income Statement Sep '18 Dec '18 Mar '19 Jun '19 Sep '19
Sales 101.26
104.61
108.77
114.14
114.36
growth rate 3.3% 4.0% 4.9% 0.2%
Op.Income 11.76
6.92
11.54
15.50
19.05
growth rate -41.2% 66.8% 34.3% 22.9%
IBT 12.60
9.32
13.27
16.33
18.90
growth rate -26.0% 42.3% 23.1% 15.8%
Net Income 12.23
8.91
13.00
15.99
18.69
growth rate -27.1% 45.9% 23.0% 16.9%
EPS
growth rate
Gross Profit 83.40
30.21
76.71
81.15
79.19
growth rate -63.8% 154.0% 5.8% -2.4%
R&D 13.09
-38.96
15.05
growth rate -100.0% 100.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (79.07)

YOY Growth Grade:

D (38.37)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 43.57 43.57 35.24
EPS / Growth 36.3% 1.46 5.5%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 20.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 5.5% 20.7% 20.7%
Future PE 11.00 40.06 40.06
Future EPS 2.49 9.55 9.55
Value Price
MOS %
6.76
-89.3%
94.55
49.0%
94.55
49.0%
MOS Price 3.38 47.27 47.27
IRT 22.13 11.34 11.34

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.